Steven Mah
Stock Analyst at TD Cowen
(2.29)
# 1,475
Out of 4,667 analysts
31
Total ratings
37.5%
Success rate
12.12%
Average return
Main Sectors:
Stocks Rated by Steven Mah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLFS BioLife Solutions | Maintains: Buy | $28 → $31 | $25.82 | +20.08% | 2 | Nov 13, 2024 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $65 | $41.84 | +55.35% | 2 | Jun 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $280 → $120 | $6.39 | +1,777.93% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $5.70 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $19.41 | +116.44% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $2.72 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $3.94 | +153.67% | 1 | Feb 22, 2023 | |
| ME 23andMe Holding Co. | Initiates: Outperform | $120 | $3.36 | +3,471.43% | 1 | Sep 22, 2022 | |
| ABSI Absci | Upgrades: Outperform | n/a | $2.64 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $4.46 | +370.85% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $155 | $169.62 | -8.62% | 4 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $2.23 | +1,157.81% | 1 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $17.25 | +711.83% | 3 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $52 | $1.77 | +2,846.18% | 3 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $340 → $415 | $133.25 | +211.44% | 4 | Dec 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $80 | $2.75 | +2,814.39% | 1 | Dec 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $168 → $250 | $38.04 | +557.20% | 1 | Jul 8, 2020 |
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $25.82
Upside: +20.08%
Twist Bioscience
Jun 13, 2024
Maintains: Buy
Price Target: $55 → $65
Current: $41.84
Upside: +55.35%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280 → $120
Current: $6.39
Upside: +1,777.93%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $5.70
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $19.41
Upside: +116.44%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $2.72
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $3.94
Upside: +153.67%
23andMe Holding Co.
Sep 22, 2022
Initiates: Outperform
Price Target: $120
Current: $3.36
Upside: +3,471.43%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $2.64
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $4.46
Upside: +370.85%
Jul 6, 2021
Maintains: Overweight
Price Target: $150 → $155
Current: $169.62
Upside: -8.62%
May 11, 2021
Initiates: Overweight
Price Target: $28
Current: $2.23
Upside: +1,157.81%
Mar 5, 2021
Maintains: Overweight
Price Target: $135 → $140
Current: $17.25
Upside: +711.83%
Feb 11, 2021
Upgrades: Overweight
Price Target: $20 → $52
Current: $1.77
Upside: +2,846.18%
Dec 22, 2020
Upgrades: Overweight
Price Target: $340 → $415
Current: $133.25
Upside: +211.44%
Dec 16, 2020
Upgrades: Overweight
Price Target: $40 → $80
Current: $2.75
Upside: +2,814.39%
Jul 8, 2020
Maintains: Overweight
Price Target: $168 → $250
Current: $38.04
Upside: +557.20%